Please login to the form below

Not currently logged in
Email:
Password:

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

AZ

Breast cancer patients in the US may soon receive a new treatment in the form of Lynparza (olaparib) tablets, after the drug won a priority review from the Food and Drug Administration (FDA).

The PARP inhibitor - co-developed and co-commercialised by AstraZeneca (AZ) and Merck & Co - is under consideration for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy.

Lynparza was first approved in the US as a capsule formulation as maintenance therapy to treat ovarian cancer and if the tablet formulation achieves the same result then the drug will be the first approved PARP inhibitor outside ovarian cancer.

Sean Bohen, executive vice president, global medicines development and chief medical officer, AstraZeneca, said: “This is an important milestone for Lynparza as the PARP inhibitor has shown a significant benefit for patients outside ovarian cancer.”

The FDA granted the status based on the phase III OlympiAD trial in which patients with breast cancer on Lynparza tablets saw a reduced risk of disease progression or death by 42% compared to those on chemotherapy.

Bohen added: “The OlympiAD results mark the first time a targeted therapy shows benefit over the current standard of care for patients with HER2-negative gBRCA-mutated metastatic breast cancer.”

Alongside its maintenance therapy indication, the medicine is indicated for use in adult patients with deleterious or suspected deleterious gBRCA-mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy.

Article by
Gemma Jones

19th October 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...